Lipocine Inc. (NASDAQ:LPCN)
| Market Cap | $16.39M-54.5% |
| Revenue (ttm) | $3.74M-13.4% |
| Net Income | -$9.33M-70.4% |
| EPS | -$1.36-32.0% |
| Shares Out | 11.07M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 219,941 |
| Open | $1.42 |
| Previous Close | $1.50 |
| Day's Range | $1.42 - $1.53 |
| 52-Week Range | $1.36 - $12.37 |
| Beta | 0.50 |
| Analysts | Buy |
| Price Target | $4.00(+170.27%) |
| Earnings Date | Mar 8, 2027 |
About LPCN
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost investigational therapy is TLANDO, an oral solution for testosterone replacement. The company's development pipeline also encompasses several other promising candidates: LPCN 1144: An orally administered prodrug derived from bioidentical testosterone, which has successfully completed Phase II clinical trials for the treatment of non-cirrhotic non-alcoholic steatohepatitis. LPCN 1111: An oral prodrug of testosterone tridecanoate, engineered for once-daily administration, and having also concluded Phase II clinical studies in men experiencing hypogonadism. LPCN 1148: A novel prodrug combining testosterone and testosterone laurate, designed for the management of decompensated cirrhosis. LPCN 1154: An investigational new drug application has been submitted to initiate a Phase 2 study targeting Postpartum Depression. LPCN 2101: A compound intended for women with epilepsy, which has progressed beyond its pre-clinical study phase. LPCN 1107: An oral hydroxyprogesterone caproate product, which has completed its dose-finding Phase II clinical trial aimed at preventing recurrent preterm birth. The corporate headquarters for Lipocine Inc. are located in Salt Lake City, Utah.
Lipocine Inc. Stock Analysis — InsiderScore
Lipocine Inc. scored higher than 36% of companies evaluated by InsiderBuying, and ranked 48th out of 99 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Lipocine Inc. bought $161.7K of stock across 5 purchases in the last 90 days, the largest of them $40.0K.
The average purchase added about 11% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating LPCN in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 8, 2027Earnings report
$LPCN stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in LPCN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by LPCN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
LPCN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New LPCN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to LPCN from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in LPCN
| VTIVanguard Morningstar Total Stock Market ETF | $162.01K |
| VXFVanguard Extended Market ETF | $126.79K |
| DFSUDimensional - US Sustainability Core 1 ETF | $7.77K |
| DCORU.S. Core Equity 1 Portfolio ETF Class Shares | $7.67K |
| DFMCU.S. Micro Cap Portfolio ETF | $7.56K |
| DFACDimensional - US Core Equity 2 ETF | $7.19K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from LPCN’s recent data — informational, not investment advice
What’s Behind the Score
News check: First Phase 3 dosing in BLOOM PPD study and Q3 2026 earnings announcement represent concrete clinical and business progress with positive implications.
Recent Insider Activity
Insider Score Trend Over Time
+21.1 since Oct 1Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
